La nouvelle étude fournit des informations sur la biodisponibilité des formulations de cannabis thérapeutique à des fins thérapeutiques NEW YORK, 27 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, une d ...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...

H.C. Wainwright 4th Annual Kidney Virtual Conference Date: July 14, 2025 Presentation Time: 3:00 pm CEST / 9:00 am EDT Attendees: Frank Weber, CEO; Julia Neugebauer, COO Virtual conference Link to ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

Net Profit: $3,253,635, compared to $812,139 for the year ended March 31, 2024—an increase of $2,441,496, representing a 300.63% year-over-year improvement.

“Since becoming Evofem’s sourcing partner for PHEXXI in March 2025, we have made rapid and significant progress,” said Jed Latkin, CEO of Windtree Therapeutics. “With this manufacturing contract inked ...

J.P. Morgan, Morgan Stanley, Guggenheim Securities and Cantor acted as joint book-running managers for the offering.

Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results ...

The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a ...

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...

Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced ...

The Company is evaluating its capital requirements and reviewing its options with regards to fund-raising through the issuance of securities. As at the date hereof, there is no certainty that any such ...